Wegovy 7.2mg: What the Higher Dose Means
Wegovy 7.2mg is the highest licensed weekly dose of semaglutide for weight management. It is an optional maintenance dose for adults with obesity and can only be considered after at least four weeks on 2.4mg. In the main STEP UP analysis, average weight loss at 72 weeks was 18.7% with 7.2mg and 15.6% with 2.4mg. The higher dose caused more gastrointestinal side effects and abnormal skin sensations, so the decision to increase must be made with your prescriber.
Wegovy injection is available in a 7.2mg weekly dose for some adults with obesity. It is the same active medicine, semaglutide, at a higher maintenance dose. It is not a starting dose and it is not intended for everyone taking Wegovy. This guide explains who may be considered for 7.2mg, what STEP UP found and what to discuss with your prescriber before increasing.
What is Wegovy 7.2mg?
Wegovy contains semaglutide, a GLP-1 receptor agonist that helps regulate appetite and calorie intake. The 7.2mg dose is an additional maintenance option for adults with obesity. It was authorised in January 2026, initially using three 2.4mg injections on the same day. The MHRA then authorised a single-dose 7.2mg pen in April 2026. Happy Pharmacy currently supplies a four-week pack containing four single-use 7.2mg pens, subject to clinical assessment and availability.
Worth knowing
The 7.2mg pen contains the same active ingredient as lower Wegovy doses. A higher dose is considered only when clinically needed. Many people remain on 2.4mg or a lower tolerated dose.
How do you reach the 7.2mg dose?
Treatment starts at 0.25mg once weekly and normally increases every four weeks until the 2.4mg maintenance dose is reached. After at least four weeks on 2.4mg, a prescriber may consider 7.2mg if it is needed for an adult with obesity. This means the earliest possible move is at the start of week 21, although dose escalation may take longer. The Wegovy dose schedule explains the standard steps in more detail.
Heights show the order of the steps and are not to scale.
| Step | Weekly dose | Minimum time at this dose |
|---|---|---|
| 1 | 0.25mg | 4 weeks |
| 2 | 0.5mg | 4 weeks |
| 3 | 1mg | 4 weeks |
| 4 | 1.7mg | 4 weeks |
| 5 | 2.4mg | At least 4 weeks before considering 7.2mg |
| 6 | 7.2mg | Maintenance, if your prescriber considers it appropriate |
Your prescriber may delay an increase or return you to the previous dose if significant gastrointestinal symptoms occur. Never increase the dose or combine pens unless your prescriber has given you clear instructions. If side effects are making escalation difficult, the Wegovy tolerance guide explains practical ways to manage common symptoms and when to seek help.
What did the STEP UP trial find?
STEP UP was a 72-week randomised trial involving 1,407 adults with obesity who did not have diabetes. Participants received semaglutide 7.2mg, semaglutide 2.4mg or placebo alongside a reduced-calorie diet and increased physical activity. The main analysis included participants whether or not they stopped treatment or used another weight-management intervention. A second analysis estimated what might have happened if everyone had remained on their assigned treatment.
Average weight loss at 72 weeks (STEP UP)
Bars are drawn to scale against a 25% maximum.
| Analysis | Wegovy 7.2mg | Wegovy 2.4mg | Placebo |
|---|---|---|---|
| If everyone stayed on treatment | 20.7% | 17.5% | 2.4% |
| Including people who stopped early | 18.7% | 15.6% | 3.9% |
In the main analysis, average weight loss was 18.7% with 7.2mg and 15.6% with 2.4mg, a difference of 3.1 percentage points. The analysis assuming continued treatment reported 20.7% and 17.5%, a difference of 3.2 percentage points. In the main analysis, 31.2% of participants on 7.2mg lost at least 25% of their starting weight, compared with 15.3% on 2.4mg. These are group averages from a controlled trial, not a forecast for an individual. The trial also excluded people with diabetes, so its headline figures should not be applied to every patient. The Wegovy results timeline explains how progress can differ over time.
What side effects were reported at 7.2mg?
In STEP UP, about 71% of participants taking 7.2 mg reported digestive side effects, compared with about 61% taking 2.4 mg.
Some participants reported tingling, burning or unusually sensitive skin. These symptoms are known as dysaesthesia and were more common at 7.2 mg. In the UK prescribing information, most cases were mild or moderate and resolved while people stayed on treatment. Tell your prescriber if you develop new or persistent symptoms.
| Side effect measure in STEP UP | 7.2mg | 2.4mg |
|---|---|---|
| Gastrointestinal events | About 71% | About 61% |
Do not try to manage severe symptoms by changing the dose yourself. Seek urgent medical help if you have severe stomach pain that does not go away, cannot keep fluids down, or suddenly notice a change in vision. Call 999 for difficulty breathing or swelling of your throat. The Wegovy side effects guide explains common effects and red flags in more detail.
Who may be considered for Wegovy 7.2mg?
May be worth discussing
- You are an adult who had a BMI of 30 kg/m² or above when you started Wegovy
- You have completed at least four weeks on 2.4mg
- You are tolerating 2.4mg and your prescriber considers further weight reduction clinically appropriate
7.2mg may not be appropriate
- Your BMI was below 30 kg/m² when you started Wegovy
- You have not yet reached or tolerated 2.4mg
- You have significant side effects or another reason your prescriber advises against increasing
A plateau does not automatically mean that the dose should increase. Your prescriber will review your response, side effects, medical history and current BMI before deciding whether 7.2mg is appropriate. The Wegovy plateau guide explains other reasons progress may slow and what to review first.
Important
Never increase your dose or take extra injections without explicit instructions from your prescriber. The 7.2mg dose is not licensed as a starting dose, is not intended for adolescents, and is not the dose used for Wegovy's cardiovascular risk-reduction indication.
Is 7.2mg automatically better than 2.4mg?
No. STEP UP showed a greater average reduction in body weight with 7.2mg, but it also showed more gastrointestinal side effects and much more dysaesthesia. A higher number on the pen does not make it the right dose for every person. The useful question is whether the likely additional benefit outweighs the extra burden and risk for you.
If 2.4mg is working and you are comfortable on it, there may be no reason to increase. If progress is limited, your prescriber should first check how long you have been at the maintenance dose, whether doses have been missed, how side effects are affecting food and fluid intake, and whether another treatment strategy would be more suitable.
What should you discuss before stepping up?
- Whether you meet the licensed criteria for the 7.2mg maintenance dose
- How long you have taken 2.4mg and whether side effects have settled
- Which device you will receive and how its injection technique and storage differ from a FlexTouch pen
- What benefit would make the increase worthwhile and when your response will be reviewed
- What to do if nausea, vomiting, diarrhoea, constipation or altered skin sensations become troublesome
The aim is not to reach the highest possible dose. It is to use the lowest appropriate dose that provides worthwhile benefit with acceptable side effects. Your prescriber may advise remaining on 2.4mg, delaying an increase, or returning to the previous dose if symptoms become significant.
Frequently asked questions
Discuss Your Wegovy Dose With Our Pharmacy Team
Complete a confidential online assessment. A UK prescriber will review your current dose, treatment response and medical history before deciding whether Wegovy and any dose increase are suitable.
View Wegovy Treatment Options → Prescription treatment is supplied only after clinical assessment.References
- Wegovy 7.2mg Summary of Product Characteristics. Electronic Medicines Compendium, updated October 2026.
- MHRA: single-dose Wegovy 7.2mg pen approved for adults with obesity. 14 April 2026.
- Wharton S, et al. Once-weekly semaglutide 7.2mg in adults with obesity (STEP UP). Lancet Diabetes & Endocrinology, 2025.
- Wegovy 7.2 mg UK patient leaflet and pen instructions
Medically Reviewed by Our GPhC-Registered Pharmacists

